Mel Robbins, Menopause, and What Clinicians Should Actually Tell Their Patients

Why Mel Robbins Matters to Your Clinical Practice

When a patient walks in holding her phone with a Mel Robbins podcast episode queued up, she is not just a fan. She is a woman who has finally found language for what is happening in her body. Robbins, the bestselling author and podcast host, has described her own perimenopause experience across multiple public platforms, including her podcast "The Mel Robbins Podcast," discussing symptoms such as disrupted sleep, mood shifts, and cognitive fog before she was formally assessed and started on hormone therapy.

She has said, on the record, that she wishes she had known sooner. That single statement is a clinical opportunity.

The Menopause Society's 2023 position statement notes that the majority of women experience vasomotor symptoms and that the duration of those symptoms averages 7.4 years, though for many women the window extends well beyond a decade. When a public figure names those symptoms and says "this happened to me and I got help," your patients pay attention in ways that a pamphlet cannot replicate.

Your job is to meet them there, with accuracy.

What Mel Robbins Has Said Publicly (and How to Use It Clinically)

Robbins has been explicit that she uses hormone therapy and that she credits it with improving her quality of life. In multiple podcast conversations she has referenced brain fog, sleep disruption, and what she describes as a loss of herself before receiving care. These are not dramatizations. They map directly onto the clinical phenotype of perimenopause.

The Symptoms She Named

The symptoms Robbins has described publicly include:

• Sleep disruption and insomnia
• Mood instability and anxiety
• Cognitive changes ("brain fog")
• Fatigue disproportionate to activity level
• A general sense of "something is wrong" before any formal diagnosis

Each of these has a documented biological basis. Estradiol fluctuations during perimenopause alter serotonin, norepinephrine, and GABA neurotransmission, which directly drives mood and sleep architecture changes. The "something is wrong" feeling is often the first symptom your patient presents with, years before she or her clinician frames it as a hormonal transition.

Why the Diagnosis Is Frequently Delayed

A 2021 survey published in Menopause found that many women saw three or more clinicians before receiving a perimenopause diagnosis. The delay is not random. Women presenting with anxiety, insomnia, or cognitive complaints are frequently assessed and treated for those conditions in isolation, without a hormone-status workup. Robbins's public statements echo this pattern almost exactly.

When your patient says "Mel Robbins described exactly what I've been going through," she is giving you a diagnostic shortcut. Ask about menstrual cycle changes first.

The Clinical Science Behind HRT: What the Evidence Actually Shows

Hormone therapy remains the most effective treatment for menopausal vasomotor symptoms. That is not an opinion. The Menopause Society's 2022 hormone therapy position statement states that for women under 60 or within 10 years of menopause onset, the benefits of HRT generally outweigh the risks for the vast majority of healthy women without contraindications.

Timing Matters: The "Window of Opportunity"

The cardiovascular benefit of estrogen therapy is time-dependent. The KRONOS Early Estrogen Prevention Study (KEEPS) demonstrated that women who initiated estrogen within 6 years of menopause had favorable effects on atherosclerosis progression compared with those who initiated later. This is the clinical rationale for the "timing hypothesis," which the WHI misapplication obscured for nearly two decades.

The Women's Health Initiative (WHI) Memory Study follow-up data showed that cognitive outcomes diverged sharply based on age at initiation. Women initiating conjugated equine estrogen (CEE) plus medroxyprogesterone acetate (MPA) after age 65 had worse cognitive outcomes than those starting at younger ages. This is why initiating HRT at the first sign of perimenopause, not years into post-menopause, changes the benefit-risk calculation.

Formulation Choices and Female-Specific Pharmacology

Not all HRT is equivalent. The WHI used oral CEE plus MPA, a combination that does not represent the full range of available therapies. Sex-specific pharmacokinetic differences are real:

• Oral estrogens undergo first-pass hepatic metabolism, raising sex hormone-binding globulin (SHBG), triglycerides, and CRP in some women.
• Transdermal estradiol bypasses hepatic first-pass metabolism and carries a lower risk of venous thromboembolism (VTE). A large UK cohort study published in the BMJ found that transdermal estrogen was not associated with increased VTE risk, whereas oral estrogen was.
• Micronized progesterone (Prometrium) has a more favorable cardiovascular and breast safety profile than synthetic progestins. The E3N cohort found that the combination of transdermal estradiol with micronized progesterone did not increase breast cancer risk over 8 years of follow-up.

These distinctions matter when your patient asks: "Is the HRT Mel Robbins takes the same as what the WHI said was dangerous?"

What About Breast Cancer Risk?

This is the question every patient asks. The answer requires precision.

The 2019 Collaborative Group meta-analysis in the Lancet found that all types of HRT except vaginal estrogen were associated with a small increase in breast cancer risk, but the absolute risk increase for estrogen-only therapy in women without a uterus was smaller than for combined therapy. For context, the same analysis noted that two units of alcohol per day confer a comparable or greater breast cancer risk increase than 5 years of combined HRT. Your patient deserves that comparison.

Women with BRCA1/2 mutations require individual counseling and likely involvement of a genetic counselor before HRT initiation.

Life-Stage Framework: Perimenopause, Menopause, and Post-Menopause

Perimenopause (Typically Ages 40-51)

This is the stage Robbins was in when her symptoms began. Menstrual cycles become irregular, FSH levels fluctuate, and estradiol levels can be paradoxically elevated before declining. A single FSH is not diagnostic. The 2023 ACOG Clinical Practice Bulletin on Menopause recommends against relying on FSH alone to diagnose perimenopause in symptomatic women.

Symptomatic perimenopausal women who want hormonal management but have not yet reached menopause need to understand that low-dose combined oral contraceptives can suppress symptoms AND provide contraception, since ovulation can still occur sporadically. This is a point that is frequently missed.

Menopause (12 months of amenorrhea)

At this stage, FSH is reliably elevated and estradiol reliably low. Standard HRT formulations apply. The benefit-risk profile is most favorable for women who initiate within the first 10 years.

Post-Menopause (Beyond the 10-Year Window)

Initiating HRT more than 10 years after the final menstrual period or after age 60 requires individualized risk assessment. The cardiovascular and cognitive benefit-risk profile shifts. Genitourinary syndrome of menopause (GSM), which includes vaginal dryness, dyspareunia, and urinary urgency, can be treated with low-dose local vaginal estrogen at any age without the systemic risk profile of systemic HRT. ACOG Practice Bulletin No. 141 supports this approach.

Women-Specific Conditions That Intersect with Menopause

Several conditions your patients may already carry interact directly with menopause and HRT decisions.

PCOS

Women with polycystic ovary syndrome reach menopause an average of 2 years later than women without PCOS, due to higher antral follicle counts. However, their perimenopause may be harder to recognize because irregular cycles are already their baseline. A 2020 review in Fertility and Sterility found that women with PCOS have a distinct hormonal trajectory into menopause that clinicians frequently misread. Testosterone levels may remain relatively higher, which can mask classic perimenopausal symptom patterns.

Thyroid Disease

Postpartum thyroiditis and Hashimoto's thyroiditis affect roughly 5-10% of women and often produce symptoms that mimic perimenopause: fatigue, cognitive slowing, mood changes, and weight gain. The American Thyroid Association guidelines recommend TSH screening for any woman presenting with these symptoms before attributing them solely to menopause. Run the TSH.

Female Pattern Hair Loss and Hormonal Acne

Both can flare during perimenopause as the androgen-to-estrogen ratio shifts. Loss of estrogen also worsens female pattern hair loss (androgenetic alopecia). HRT does not reliably reverse hair loss but may slow progression. Hormonal acne in perimenopause responds to estrogen-dominant regimens; adding spironolactone 25-100 mg/day is an evidence-supported adjunct. A review in JAMA Dermatology supports spironolactone use for hormonal acne in adult women.

Osteoporosis

Estrogen is the primary regulator of bone remodeling in women. Bone loss accelerates sharply in the first 3-5 years after menopause. The ACOG Committee Opinion on Bone Health recommends DEXA screening at age 65, or earlier for women with risk factors including early menopause (before age 45). HRT is not FDA-approved as a primary osteoporosis treatment, but it does preserve bone mineral density and may be a reasonable dual-purpose option for symptomatic women with low bone density who are already candidates for HRT.

Cardiovascular Risk

Women who experience early menopause (before age 45) or premature ovarian insufficiency (POI, before age 40) have significantly elevated long-term cardiovascular risk. A meta-analysis in the European Heart Journal found a 50% increased risk of coronary heart disease in women with early menopause. These women should be considered for HRT until at least the average age of natural menopause, regardless of symptom burden.

Pregnancy, Lactation, and Contraception: A Required Clinical Note

HRT is contraindicated in confirmed pregnancy. This must be stated clearly in any clinical conversation about menopause management.

The Perimenopause Contraception Gap

Perimenopause is not infertility. ACOG Practice Bulletin No. 128 on Diagnosis of Abnormal Uterine Bleeding and related guidance confirm that women can ovulate sporadically throughout perimenopause. Unintended pregnancy rates in women over 40 are lower than in younger women, but they are not zero, and the outcomes of unintended pregnancy in perimenopausal women carry higher obstetric risk.

The clinical rule: Contraception is required until 12 consecutive months of amenorrhea in women over 50, and until 24 months of amenorrhea in women under 50.

Low-dose combined oral contraceptives (COCs) serve a dual function in perimenopausal women who are not at elevated VTE or cardiovascular risk: they suppress vasomotor symptoms AND prevent pregnancy. The transition from COC to HRT can be made at age 50-51 or when the woman prefers to stop contraception.

Progestin-releasing IUDs (levonorgestrel IUD) provide contraception and, in women using systemic estrogen, can serve as the progestogen component of HRT (off-label, but supported by evidence reviewed in Menopause journal).

Lactation

Standard systemic HRT is not appropriate during lactation. Estrogen suppresses milk production. Women who are postpartum and lactating and who are experiencing significant symptoms should be assessed for postpartum thyroiditis and postpartum depression before any hormonal intervention is considered. Low-dose local vaginal estrogen may be used cautiously for GSM during lactation, as systemic absorption is minimal at standard doses, but data in this specific population are limited and the prescribing clinician should document the risk-benefit discussion.

The Evidence Gap: What We Do Not Know About Women and HRT

Women were systematically underrepresented in cardiovascular and pharmacological trials for decades. The WHI, despite its size, enrolled women at a mean age of 63, years beyond the perimenopausal window most clinicians now recognize as the optimal initiation period. This means that much of what we know about HRT's cardiovascular effects in the 45-55 age group is extrapolated from subgroup analyses, not from primary-powered trials in that population.

The DOPS trial, a Danish randomized controlled trial, did enroll women at the time of menopause and showed a significant reduction in the composite of death, myocardial infarction, and heart failure in the HRT group after 10 years. But it was smaller and has not been replicated at scale.

The sex-disaggregated data on micronized progesterone versus synthetic progestins, in particular, come largely from observational cohorts rather than randomized trials. The E3N findings are compelling but not definitive. When your patient asks whether transdermal estradiol plus micronized progesterone is "proven safe," the accurate answer is: the observational data are consistently reassuring, but we lack a large randomized trial powered specifically for this formulation in perimenopausal women.

Say that. Your patients can handle nuance, and your candor is what builds trust.

What Clinicians Should Actually Tell Patients Who Mention Mel Robbins

The "Mel Robbins Moment" is a clinical framework for the conversation that happens when a patient arrives already primed by celebrity advocacy. It is not about validating celebrity medicine. It is about redirecting a patient's engagement toward evidence.

Step 1. Acknowledge the symptoms she named. "You mentioned brain fog and sleep disruption. Those are real symptoms with a biological explanation. Let's talk about where you are in your cycle right now."

Step 2. Take a menstrual history before ordering labs. Cycle irregularity is the first clinical sign of perimenopause. Lab values fluctuate too widely in early perimenopause to be definitive. A detailed menstrual history is more informative than a single FSH in a woman with an intact menstrual cycle.

Step 3. Contextualize HRT honestly. Not "HRT is safe" or "HRT is dangerous." The actual message: "For healthy women under 60 without specific contraindications, the benefits of hormone therapy generally outweigh the risks, especially when started within 10 years of your last period. Your individual risk profile shapes exactly what formulation and dose makes sense for you."

Step 4. Address contraception before addressing hormones. Ask directly: "Are you using contraception? Are you trying to conceive?" Do not assume perimenopause equals infertility.

Step 5. Return to the evidence gap. "Some of what Mel Robbins experienced, and what you're experiencing, hasn't been studied as well as it should be in women your age. That's a gap in the research, not a reason to dismiss the symptoms."

Step 6. Set a concrete follow-up. "Let's check in in 8-12 weeks after you start [intervention]. We'll assess symptom response and reassess the plan."

Who This Approach Is Right For, and Who Needs a Different Path

HRT as Robbins describes it is most appropriate for:

• Healthy women aged 45-59 with bothersome vasomotor symptoms within 10 years of menopause
• Women with premature ovarian insufficiency (before age 40), who have a strong indication for HRT regardless of symptom severity
• Women with early menopause (before age 45), for cardiovascular and bone protection

HRT requires individual risk assessment and may not be the right first step for:

• Women with a personal history of hormone receptor-positive breast cancer (consultation with oncology is required)
• Women with active or recent VTE or cardiovascular event
• Women with undiagnosed abnormal uterine bleeding
• Women who are pregnant or may be pregnant
• Women with active liver disease

Non-hormonal alternatives with evidence for vasomotor symptoms include fezolinetant (Veoza), FDA-approved in 2023 as the first non-hormonal neurokinin B receptor antagonist for menopause, approved based on the SKYLIGHT trials showing significant reduction in moderate-to-severe hot flash frequency. This option is particularly relevant for women with breast cancer histories.

Venlafaxine 37.5-75 mg/day and paroxetine 7.5 mg/day (Brisdelle) also have evidence for vasomotor symptoms. ACOG Practice Bulletin 141 includes both as second-line options.

The Cultural Moment and the Clinical Responsibility

Mel Robbins reaching tens of millions of women with the message "I was struggling, I found out it was perimenopause, and I got help" does something that clinical guidelines cannot: it reduces shame. Women have been told for generations that menopause symptoms are normal, manageable without medical intervention, or simply part of aging. The data do not support that dismissal.

A Menopause Society survey found that fewer than 20% of OB-GYN residency programs in the United States provide formal menopause training, and a 2019 survey published in Menopause found that only 6.8% of ob-gyn residency programs offered a dedicated menopause curriculum. The knowledge gap is not only in the patient population.

When Robbins says "I wish I had known sooner," she is describing a failure of the medical system to proactively educate women about a universal biological transition. Your clinical practice is one concrete point where that failure can stop.